Mindset Pharma is a leader in developing next-generation psychedelic medicines to treat neurological and psychiatric disorders.

ABOUT US

Company Overview

Mindset Pharma is a Toronto-based drug discovery business focused on creating novel and patentable psychedelic compounds for the treatment of neurological and psychiatric disorders.

Play Video

Pipeline

Mindset has developed 4 families of novel, next-generation psychedelics with differentiated characteristics and improved safety profiles. Read More

Click to enlarge

Family

Family 1 / MSP-1014: Psilocybin-like conjugate.

Family 2: High-potency, short-acting, psilocybin-like.

Family 3: Low-potency, long-duration for micro-dosing

Family 4: DMT/ 5-MeO-DMT-inspired compounds

Lead Identification

Lead Optimization

IND-Enabling

Clinical
Phase 1

Recent News

Aug 09, 2022
Mindset Pharma CEO, James Lanthier, Issues Letter to Shareholders
Jul 06, 2022
Mindset Pharma Receives Allowance for Patent Application Covering its Short-Duration Novel Psychedelic Medications for The Treatment of Central Nervous System Disorders
Jun 29, 2022
Mindset Pharma Announces Development of Novel, Optimized, Intranasal Formulation
Jun 22, 2022
Mindset Pharma and Top Psychiatric Research Hospital, CAMH, Enter Innovative Collaboration to Build Molecular Profile of MSP-1014 Compared to Psilocybin
Subscribe for latest news